eligibility_summary
Inclusion: Adults ≥18 with confirmed CLL/SLL, untreated or no prior fludarabine/bendamustine/rituximab, chlorambucil none/<4 wks, meets iwCLL treatment criteria, ECOG ≤2, adequate organ function, contraception, life expectancy ≥6 mo. Exclusion: other malignancy <1 yr or Richter, serious organ/cardiovascular disease, HIV/HBV/active infection or CNS involvement, recent major surgery or malabsorption, strong CYP3A inhibitors, pregnancy/lactation, bleeding risk/thrombosis, hypersensitivity.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1b single-arm trial in newly diagnosed CLL/SLL testing a chemo-free, limited-duration ZGR regimen: zanubrutinib + obinutuzumab + lenalidomide, with lenalidomide dose escalation to define RP2D and deepen remission to MRD-negativity. Zanubrutinib: oral small-molecule covalent BTK inhibitor, blocking B-cell receptor signaling and survival. Obinutuzumab: type II, glycoengineered anti-CD20 monoclonal antibody driving direct cell death and potent ADCC/ADCP. Lenalidomide: oral IMiD that binds cereblon to degrade Ikaros/Aiolos, enhancing T- and NK-cell function, cytokine modulation, and anti-tumor immunity. Targets/pathways: malignant CD20+ B cells, BTK/BCR pathway, CD20-mediated cytotoxicity, CRBN-dependent immune activation in T cells, NK cells, and macrophages/microenvironment.